Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

Harry Ross Powers,¹ Moshe Bachar,¹ Natasha Savage,²,³ Michael Toscano,² Paul M. Dainer³,⁴

Departments of ¹Medicine and ²Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA; ³Charlie Norwood Veteran Affairs Medical Center, Augusta, GA; ⁴Section of Hematology/Oncology, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.

Introduction

Acute myeloid leukemia (AML) is a clonal, hematological malignancy of myeloid progenitor cells. These progenitor blast cells accumulate in the bone marrow and peripheral blood, eventually disrupting normal hematopoiesis and leading clinically to anemia, neutropenia and thrombocytopenia.¹ The prognosis for AML is variable, and reflects a number of clinical and genetic factors.²

Currently, AML is considered treatable and curative in many cases with a remission-induction chemotherapy regimen followed by consolidative chemotherapy and, in many cases, hematopoietic stem cell transplant in first or subsequent remissions. In 1973, a standard regimen of 7 days of continuous infusion cytarabine and 3 days of daunorubicin was established. The initial remission rates have varied from 55-90% of patients after 7+3 therapy in patient cohorts with a median age of 50;³,⁴ however, 20-30% of young patients and 40-50% of older patients will experience primary induction failure.⁵ The 5-year survival rate for recurrent AML is only 11%.⁶ There still remains considerable variability in assigning appropriate treatment for primary-refractory and recurrent leukemia.⁷ Azacitidine is a hypomethylating agent shown to be more effective compared to best support care in elderly patients or patients with poor performance state and serious comorbidities.⁷ Azacitidine acts by inhibiting DNA methyltransferase once it is incorporated in the growing DNA strand.⁸ The drug’s limited efficacy in AML was demonstrated as far back as the 1970’s.⁹ Nevertheless, it did not become commercially available until 2004 when approved as the first drug for the treatment of myelodysplastic syndromes (MDS). Renewed interest in its potential to treat AML quickly followed. Several additional clinical studies have demonstrated its efficacy in treating relapsed or refractory AML.⁵,¹⁰,¹¹ We recently treated a patient whose case illuminates the potential of azacitidine therapy in refractory AML with monocytic features under severely adverse conditions.

Case Report

A 57-year-old Filipino man presented with de novo AML, hyperuricemia, fulminant acute renal failure with a creatinine of 9.9 mg/dL and leukocytosis (80.6×10³/mm³), features associated with an increased risk of early death.¹² He initially presented to the Emergency Department complaining of progressive dyspnea, anorexia and a 20-pound weight loss over the prior three to four weeks. His past medical history was significant for mitral valve replacement for mitral valve prolapse, seizure disorder, hyperlipidemia, cigarette smoking and heavy alcohol use. He denied fever, night sweats, pruritus, rash, or cough. His family history was non-contributory. His vital signs and body temperature were normal. Physical exam was significant for a grade II/VI systolic ejection murmur in left upper sternal border, bibasilar crackles on lung auscultation and trace pretilial edema. No lymphadenopathy or hepatosplenomegaly were noted. His admission CBC was significant for a white blood cell count (WBC) of 80.6×10³/mm³ with differential of 13% segmented neutrophils, 3% bands, 4% lymphocytes, and 75% monocytes with many immature forms and a platelet count of 88×10³/mm³. These results represent a marked change from his CBC done only four months previously. At that time, his CBC demonstrated a WBC of 7.8×10³/mm³ with a normal differential, a platelet count of 150×10³/mm³ and a hemoglobin of 14.6 g/dL. Bone marrow aspiration with flow cytometry, cytogenetics and fluorescent in-situ hybridization (FISH) studies demonstrated acute myeloid leukemia, WHO classification not otherwise specified (with monocytic differentiation), with 84% blasts, 3% segmented neutrophils, 2% nucleated red blood cells, 3% lymphocytes and 5% monocytes. Cytogenetic studies revealed a normal karyotype and FISH demonstrated no mutations (5q12, 5q31, 7cen, 7q31, 8cen, and 20q12) commonly observed in AML or MDS. JAK2 mutational studies were likewise negative. He received rasburicase for hyperuricemia and underwent acute hemodialysis. His hyperuricemia and acute renal failure resolved.

The patient initially received non-anthracycline based induction therapy with fludarabine (15 mg/m² IV BID for 4 days) and cytarabine...
Non commercial use only

azacitidine therapy (C). The WBC normalized only after induction (red box) included fludarabine and cytarabine, and the second induction marked after a brief nadir following the second induction therapy, and only normalized after azacitidine therapy (B). Monocytes (including monoblasts and promonocytes) rebounded following the first two cycles of induction therapy and only normalized after azacitidine therapy (C).

Discussion and Conclusions

Response of refractory AML to azacitidine has been documented as far back as the 1970s. A recent clinical study assessed the efficacy of hypomethylating agents (azacitidine and decitabine) as induction, salvage, or consolidation therapy for AML. They reported that hypomethylating agents used as induction therapy resulted in a response rate of 26%; however, as salvage therapy, only one of 28 patients achieved a CR. In another study, 21% of patients treated with azacitidine for recurrent or refractory disease achieved a CR. Of this group, six patients later underwent a hematopoietic stem cell transplant (HSCT). Both studies showed a similar median overall survival (OS) of the whole cohort of 8 and 9 months, respectively; however, among the patients that achieved a CR, median OS was not reached. These results suggest that the complete responses achieved may be durable. Furthermore, a French study of 141 patients with refractory AML after intensive chemotherapy reported a 9% complete response rate following azacitidine based therapy. Among their cohort with a normal karyotype the one-year survival was 42.5%. These studies underline the efficacy of hypomethylating agents in the treatment of selected patients with relapsed or refractory AML.

Furthermore, combinations of azacitidine with other agents including epigenetic modifiers and other targeted chemotherapeutic agents have shown particular promise. A phase II trial demonstrated increased response rate in MDS with azacitidine and the HDAC inhibitor, vorinostat, compared to historic controls. Another clinical trial has shown that a combination of azacitidine and the non-specific tyrosine kinase inhibitor sorafenib may be particularly effective in treating relapsed AML with a FLT-3 mutation. Combination chemotherapy of azacitidine and gemtuzumab ozogamicin for elderly patients not qualifying for intensive induction chemotherapy has achieved a 35% CR rate in a phase II clinical trial.

Our patient is unusual because of his critical condition at presentation with extreme leukocytosis, hyperuricemia, associated acute renal failure and borderline low cardiac EF. He had cytogenetically normal AML, the most common cytogenetic risk group, which is associated with variable outcomes. While there is little data on association between response to azacitidine and AML with monocytic differentiation, there is evidence that azacitidine is an effective agent in the management of chronic myelomonocytic leukemia. It would be of interest to investigate further whether a monocytic phenotype is particularly responsive to azacitidine therapy. The aggressiveness of his leukemia is notable as well with the rapid rise of his white blood count to over 100×10^3/mm^3 only two weeks after completing his second induction course. Far more surprising, he developed significant thrombocytosis following two consecutive cycles of induction chemotherapy, a phenomenon observed in the 3q21q26 syndrome, although he had cytogenetically normal AML. Another possible cause for his thrombocytosis is damage to megakaryocytes after chemotherapy, which explains the presently atypical megakaryocytes in his bone marrow after the first round of induction chemotherapy. Regardless of the etiology, his platelet count returned to normal levels after azacitidine therapy. Our patient also did not experience the dose-limiting toxicities of azacitidine, such as severe bone marrow suppression and infection. There are only a few reports of patients achieving a complete remission following azacitidine after failing initial remission-induction therapy.

Azacitidine may, in select cases, become a preferred agent for salvage therapy in refracto-
ry or recurrent AML especially as a bridge to HSCT. Further prospective clinical trials with a focus on the clinical and molecular behavior are needed to assess further the optimal use of hypomethylating agents in the management of refractory AML.

References